Printed from Voxsanity (voxsanity.com.au) — NCT07275788 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
Back to Chronic Kidney Disease
Phase 1 Chronic Kidney Disease Trial, Recruiting
NCT07275788
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged between 30 and 75 years old at the time of signing the consent form
- People who have been diagnosed with Type 2 Diabetes for at least 1 year
- People who have been diagnosed with Chronic Kidney Disease (a long-term condition where the kidneys do not work as well as they should)
- People who are willing to sign a consent form, attend all study appointments, and follow the study requirements closely
Who may not be able to join:
- Women who are pregnant, breastfeeding, or planning to become pregnant within one year of receiving the study treatment, or men whose partner is planning to become pregnant in that time
- People who test positive for syphilis, HIV, hepatitis B surface antigen, or hepatitis C at the screening visit — though stable hepatitis B carriers, and people fully cleared of hepatitis C (confirmed by a negative RNA test), may still be considered (confirm with trial site)
- People who currently have, or have previously had, a cancer diagnosis — though people who have been cancer-free for more than 2 years, or whose cancer was assessed by the doctor as low-risk, may still be considered (confirm with trial site)
- People diagnosed with Type 1 Diabetes
- People who are currently receiving regular kidney dialysis (either haemodialysis or peritoneal dialysis)
- People who were hospitalised in the 2 weeks before screening due to a serious sudden complication of diabetes or kidney disease
- People who had more than one episode of very low blood sugar causing loss of consciousness in the month before screening
- People who cannot tolerate a kidney needle procedure (a procedure where a needle is inserted into the kidney)
- People diagnosed with sudden kidney injury, a kidney disease present from birth, shrinkage of the kidneys, or other kidney conditions the doctor considers disqualifying — or people who have had a kidney transplant
- People who had a serious illness affecting the whole body in the 6 months before screening that the doctor considers unsuitable for the study
- People who need long-term blood-thinning medication and, in the doctor's judgement, cannot safely stop it one week before the kidney procedure
- People with a risk of suicide, a history of a psychiatric (mental health) disorder, or a history of epilepsy
- People whose heart tracing (ECG) at screening shows a significant irregular heartbeat or heart conduction problem (second degree or above)
- People who took part in another clinical trial involving a treatment or intervention in the month before screening
- People whose doctors estimate they have less than one year to live at the time of screening
- Trial staff, doctors and coordinators involved in running this study, or their family members
- People who have any other condition that, in the doctor's judgement, could put them at greater risk or affect the trial results
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.
Contact this trial
Phone: 086-021-66111062
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Status
Recruiting
Phase
Phase 1
Sponsor
Regend Therapeutics
Registry
ClinicalTrials.gov
Start date
8 January 2026
Est. completion
1 December 2027
Where this trial is recruiting
🇨🇳 China
Primary endpoints
Adverse Event (AE) associated with the Cell Therapy
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.